ISRG Stock Analysis — Intuitive Surgical
Sector: Healthcare
AI Verdict
ISRG trades at 30.6x next year's earnings for 49.0% expected EPS growth, which is cheap for the growth on offer if its da Vinci ecosystem keeps hospitals locked in, but the overbought RSI warns of near-term downside if expectations slip.
Competitive Moat
Intuitive Surgical dominates robotic-assisted surgery with its da Vinci platform, protected by a massive installed base and high switching costs for hospitals and surgeons. Its proprietary hardware-software ecosystem and recurring revenue from instruments and service contracts create a durable competitive edge.
Summary
ISRG's da Vinci system is the backbone of robotic surgery, locking in hospitals and driving high-margin recurring revenue.
Where It Stands
Despite a -17.22% 1-year return and an RSI of 76.6 signaling overbought territory, ISRG trades at 30.6x forward earnings—well above the healthcare sector median of 22x—while analysts expect 49.0% EPS growth next year.
Key Metrics
- RSI: 76.6 — Overbought
- Trailing P/E: 45.6x
- Forward P/E: 30.6x
- PEG Ratio: 0.97
- Earnings Growth: +0.5%
- Revenue Growth: +0.2%
- Market Cap: $140.5B
- 1-Year Return: -17.22%
- 52-Week High: $603.88
- 52-Week Low: $328.57
Analyst Consensus
28 Buy · 11 Hold · 1 Sell (40 analysts)
Bull Case
ISRG's 49.0% forward EPS growth paired with a 30.6x forward P/E means you're paying a lower multiple for growth than most high-quality medtech names.
Bear Case
With an RSI of 76.6 and a trailing P/E of 45.6x, a pullback to the sector median 22x would mean a 52% valuation drop if growth expectations falter.
Catalyst to Watch
Watch for quarterly procedure growth and new system placements—any slowdown could challenge the 49.0% EPS growth baked into the price.